Purchase Order HHSN275201600006P

The Department of Health and Human Services' National Institutes of Health National Institute of Child Health and Human Development awarded a $19,210 purchase order to Horizon Genomics GMBH for "OTHER FUNCTIONS - HAP 1 KNOCKOUT CELLS & HAP1 CELLS." Horizon Genomics GMBH, a subsidiary of Haplogen GMBH, will deliver the requested HAP1 knockout and HAP1 cells under a firm fixed price contract with performance taking place in Bethesda, Maryland over a three-month period concluding in...

The National Institute of Child Health and Human Development (NICHD) awarded Genscript USA Inc. a $24,000 firm fixed-price call order under a blanket purchase agreement (BPA) for RAD knockout HEK293T cell lines. The contract was awarded on June 24, 2015, with an ultimate completion date of June 23, 2016, and performed at the NICHD's facility in Bethesda, Maryland. This procurement was not designated as a set-aside contract. Genscript USA Inc., a Piscataway, New Jersey-based biotechnology company...

This is a firm fixed-price purchase order contract awarded by the National Institute of Child Health and Human Development (NICHD), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract, valued at $21,277.24, is for the generation of a POLH/POLI knockout MRC5SV cell line and other associated services. The contract does not have a set-aside designation. Genscript is a well-established...

The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm-fixed-price purchase order contract to Genscript USA Inc., a for-profit biotechnology company, for stable cell line development services with a completion date of April 1, 2020. The contract had a potential value of $130,400.99 and was not set aside for any particular business type. Genscript provides a range of molecular biology products and services, including gene synthesis, gene editing,...

This contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Applied Stemcell, Inc., a minority-owned, woman-owned small business, for a firm-fixed-price purchase order in the amount of $63,000.00. The contract calls for the use of CRISPR gene editing technology to create two custom induced pluripotent stem cell (iPSC) reporter cell lines - one with dual gene knock-ins for albumin and alpha-fetoprotein, and...

Life Technologies Corporation, doing business as Thermo Fisher Scientific, was awarded a Blanket Purchase Agreement (BPA) call contract by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health, on May 2, 2016. The contract, valued at $9,980.00 with a firm fixed price structure, involved the supply of PR-UAS-BLA HEK293T cells in kit format for use by NCATS staff members Menghang Xia and Sri Sakamuru. The work was performed at the...

The Food and Drug Administration (FDA) awarded a purchase order to Genscript USA Inc. on July 12, 2019, for the development of a stable cell line expressing target antibody 41, with a ceiling value of $20,285.30. This firm fixed-price contract, which concluded on December 31, 2019, represents a focused procurement for specialized biotechnology services to support the FDA's research and development initiatives. The work was performed at Genscript's facility in Piscataway, New Jersey, where the...

This firm fixed-price purchase order for $18,204.88 was awarded by the Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse to Genscript USA Inc. to obtain cell lines utilizing CRISPR gene editing technology. Specifically, the contract calls for Genscript to generate knockout HEK293 and HepG2 cell lines of the MMAB and MUT genes to support studies for hereditary disorders of vitamin B12 and methylmalonic acid metabolism. No set-aside designation...

This is a firm fixed-price call order awarded to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey, by the National Institute of Child Health and Human Development (NICHD), a civilian agency within the U.S. Department of Health and Human Services. The $14,190.07 contract is for the provision of services related to host cell line and strain preparation (contract number 75N98024A00139|75N94024F00001). The contract has a period of performance ending on July 31, 2025 and...

This is a firm fixed-price purchase order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency within the U.S. Department of Health and Human Services, to Applied Stemcell, Inc. for $9,027.20. The contract, which has no set-aside designation, was awarded on April 27, 2011 for gene editing services to generate customized cell and animal models, including knockout mouse models, reporter cell lines, and stem cell models with disease-associated...